124 related articles for article (PubMed ID: 18203079)
1. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers.
Chiambaretta F; Garraffo R; Elena PP; Pouliquen P; Delval L; Rigal D; Dubray C; Goldschmidt P; Tabbara K; Cochereau I
Eur J Ophthalmol; 2008; 18(1):13-20. PubMed ID: 18203079
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Modeling of Azithromycin Eyedrops in Tears Following Single-Dose Topical Administration in Healthy Volunteers.
Wu F; Zhao X; Li X; Cui Y
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):371-378. PubMed ID: 30357610
[TBL] [Abstract][Full Text] [Related]
3. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
Walters T; Rinehart M; Krebs W; Holdbrook M
Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
[TBL] [Abstract][Full Text] [Related]
4. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers.
Raizman MB; Rubin JM; Graves AL; Rinehart M
Clin Ther; 2002 Sep; 24(9):1439-50. PubMed ID: 12380635
[TBL] [Abstract][Full Text] [Related]
5. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation.
Akpek EK; Vittitow J; Verhoeven RS; Brubaker K; Amar T; Powell KD; Boyer JL; Crean C
J Ocul Pharmacol Ther; 2009 Oct; 25(5):433-9. PubMed ID: 19857105
[TBL] [Abstract][Full Text] [Related]
6. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
Torkildsen G; O'Brien TP
Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
[TBL] [Abstract][Full Text] [Related]
7. Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits.
Amar T; Caillaud T; Elena PP
Curr Eye Res; 2008 Feb; 33(2):149-58. PubMed ID: 18293185
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of short-duration topical treatment with azithromycin oil-based eyedrops in an experimental model of corneal refractive surgery.
Merayo-Lloves J; Blanco-Mezquita T; Ibares-Frías L; Cantalapiedra-Rodríguez R; Alvarez-Barcia A
Eur J Ophthalmol; 2010; 20(6):979-88. PubMed ID: 20544676
[TBL] [Abstract][Full Text] [Related]
9. Ocular pharmacokinetics of AzaSite Xtra-2% azithromycin formulated in a DuraSite delivery system.
Si EC; Cheung PS; Bowman L; Hosseini K
Curr Eye Res; 2009 Jun; 34(6):485-91. PubMed ID: 19899983
[TBL] [Abstract][Full Text] [Related]
10. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
11. A LC-MS/MS validated method for determination of azithromycin in human tears and its application to an ocular pharmacokinetic study.
Wu F; Zhao X; Ni S; Yang B
Pharmazie; 2020 Oct; 75(10):478-482. PubMed ID: 33305720
[TBL] [Abstract][Full Text] [Related]
12. Corneal pharmacokinetics of topically applied azithromycin and clarithromycin.
Kuehne JJ; Yu AL; Holland GN; Ramaswamy A; Taban R; Mondino BJ; Yu F; Rayner SA; Giese MJ
Am J Ophthalmol; 2004 Oct; 138(4):547-53. PubMed ID: 15488779
[TBL] [Abstract][Full Text] [Related]
13. Ocular levels of azithromycin.
Tabbara KF; al-Kharashi SA; al-Mansouri SM; al-Omar OM; Cooper H; el-Asrar AM; Foulds G
Arch Ophthalmol; 1998 Dec; 116(12):1625-8. PubMed ID: 9869792
[TBL] [Abstract][Full Text] [Related]
14. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin.
Bowman LM; Si E; Pang J; Archibald R; Friedlaender M
J Ocul Pharmacol Ther; 2009 Apr; 25(2):133-9. PubMed ID: 19284320
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of azithromycin in trachoma patients: serum and tear levels.
Karcioglu ZA; El-Yazigi A; Jabak MH; Choudhury AH; Ahmed WS
Ophthalmology; 1998 Apr; 105(4):658-61. PubMed ID: 9544640
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye.
Nichols JJ; Bickle KM; Zink RC; Schiewe MD; Haque RM; Nichols KK
Eye Contact Lens; 2012 Mar; 38(2):73-9. PubMed ID: 22157392
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetic and relative bioavailability study of coated and uncoated azithromycin powder for suspension in healthy Bangladeshi male volunteers.
Sultana TA; Islam MS; Bhuiyan NH; Shohag MH; Ahmed MU; Naznin SR; Al Maruf A; Huq SM; Hasnat A
Arzneimittelforschung; 2011; 61(10):594-8. PubMed ID: 22164968
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin.
Chandra R; Liu P; Breen JD; Fisher J; Xie C; LaBadie R; Benner RJ; Benincosa LJ; Sharma A
Clin Pharmacokinet; 2007; 46(3):247-59. PubMed ID: 17328583
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence study of two azithromycin formulations in healthy subjects.
Setiawati E; Deniati SH; Yunaidi DA; Handayani LR; Harinanto G; Santoso ID; Sari AP; Rimainar A
Arzneimittelforschung; 2009; 59(9):471-5. PubMed ID: 19856795
[TBL] [Abstract][Full Text] [Related]
20. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis.
Haque RM; Torkildsen GL; Brubaker K; Zink RC; Kowalski RP; Mah FS; Pflugfelder SC
Cornea; 2010 Aug; 29(8):871-7. PubMed ID: 20508503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]